GlassScriptPhysician profile
Maia Chakerian
NPI 1598708778
$20,679.90
in general payments reported to CMS, 2019-2025
43 companies · $9,166 in 2025
The $9,166 reported for 2025 was more than what 95% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,558 · 2020: $638 · 2021: $2,349 · 2022: $1,038 · 2023: $441 · 2024: $489 · 2025: $9,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,523 · Food and Beverage: $1,433 · Travel and Lodging: $1,141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,522.50 |
| Food and Beverage | $1,432.87 |
| Travel and Lodging | $1,140.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $8,955.10 | 2024-2025 | |
| Grt US Holding, INC. | $4,167.69 | 2019 | |
| Trevena, INC. | $1,000.00 | 2021 | |
| Abbvie INC. | $871.87 | 2021-2025 | Ubrelvy, Qulipta |
| Boston Scientific Corporation | $757.77 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $755.89 | 2019-2025 | Belbuca |
| Teva Pharmaceuticals USA, INC. | $536.77 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $504.57 | 2020-2021 | |
| Merz North America, INC. | $444.53 | 2019-2023 | Xeomin |
| Allergan, INC. | $313.10 | 2019-2020 | |
| Amgen INC. | $241.99 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $194.64 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $182.44 | 2022 | |
| Stimwave Technologies Incorporated | $180.43 | 2019 | |
| Vertiflex, INC. | $146.75 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $143.23 | 2019 | |
| Radius Health, INC. | $125.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2019 | |
| Mayne Pharma Commercial LLC | $125.00 | 2023 | |
| Abbott Laboratories | $109.03 | 2019-2023 | Proclaim |
| Lundbeck LLC | $90.17 | 2021 | |
| Biodelivery Sciences International, INC. | $85.03 | 2019-2021 | |
| Scilex Pharmaceuticals INC. | $84.61 | 2020 | |
| Lilly USA, LLC | $73.36 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $62.49 | 2019-2021 | |
| Pfizer INC. | $54.82 | 2021 | |
| Tersera Therapeutics LLC | $52.52 | 2019 | |
| Sentynl Therapeutics, INC. | $52.35 | 2019 | |
| Nalu Medical, INC. | $35.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.12 | 2025 | Relistor |
| Si-Bone, INC. | $29.00 | 2020 | |
| Merz Pharmaceuticals, LLC | $25.33 | 2021 | |
| Nevro Corp. | $23.09 | 2019 | |
| Medline Industries LP | $21.69 | 2019 | |
| Saluda Medical Americas, INC. | $20.00 | 2019 | |
| Saol Therapeutics INC. | $19.50 | 2019 | |
| Redhill Biopharma INC. | $18.84 | 2021 | |
| Kaleo, INC. | $18.27 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maia Chakerian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.